Last reviewed · How we verify
ceftriaxone sodium + metronidazole
This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a nitroimidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic gram-negative, gram-positive, and anaerobic organisms.
This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a nitroimidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic gram-negative, gram-positive, and anaerobic organisms. Used for Intra-abdominal infections (including peritonitis and appendicitis), Gynecological infections, Anaerobic bacterial infections with mixed aerobic-anaerobic flora.
At a glance
| Generic name | ceftriaxone sodium + metronidazole |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Drug class | Beta-lactam antibiotic + nitroimidazole antibiotic combination |
| Target | Bacterial penicillin-binding proteins (ceftriaxone); anaerobic bacterial DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftriaxone sodium binds to penicillin-binding proteins and inhibits cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis. Metronidazole is a prodrug that generates reactive intermediates in anaerobic bacteria, causing DNA strand breaks and cell death. Together, they provide synergistic coverage for mixed aerobic-anaerobic infections.
Approved indications
- Intra-abdominal infections (including peritonitis and appendicitis)
- Gynecological infections
- Anaerobic bacterial infections with mixed aerobic-anaerobic flora
- Prophylaxis in abdominal and gynecological surgery
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Hypersensitivity reactions
- Pseudomembranous colitis
- Metallic taste (metronidazole)
Key clinical trials
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
- Povidone Iodine Versus Normal Saline in Preoperative Vaginal Cleansing Before Caesarean Section (NA)
- Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis
- Effects of Probiotic in Treatment of Persistent Diarrhea in Children (NA)
- A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor (PHASE3)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: